Isoquercetin

异槲皮苷

Report date: 2026/03/20 20:03:07

Base Information

Drug NameIsoquercetin
Drug Alias Name异槲皮素Isoquercitrin槲皮素-3-O-葡萄糖苷IsotrifoliinIsoquercitroside +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitorsAngiotensin-converting enzyme inhibitorsAldose reductase inhibitors
TargetsSignal transducer and activator of transcription 3Angiotensin-converting enzymeAldose reductase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)beta-ThalassemiaAnemia, Sickle Cell +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyFrance +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesQuercis Pharma AGQuercegen Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesChengdu University Of TcmQuercis Pharma AGThe First Medical Center of Chinese PLA General Hospital +[7] 
Inactive CompaniesQuercegen PharmaceuticalsPharmascience IncTulane University +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Anemia, Sickle CellVenous Thromboembolism +[7] 
Inactive Indicationsbeta-ThalassemiaRenal Insufficiency, ChronicKidney Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG